Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus
The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that the...
Gespeichert in:
Veröffentlicht in: | Neuroscience 2005, Vol.133 (1), p.305-313 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 313 |
---|---|
container_issue | 1 |
container_start_page | 305 |
container_title | Neuroscience |
container_volume | 133 |
creator | Freiman, I. Szabo, B. |
description | The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB
1 cannabinoid receptors. The hypothesis of the present work was that CB
1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons.
Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB
1/CB
2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10
−7 M) had no effect on EPSCs. WIN55212-2 (10
−5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10
−5 M) was prevented by the CB
1 antagonist
N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10
−6 M). WIN55212-2 (10
−5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10
−5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10
−3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10
−5 M) did not change the firing of these neurons.
The results show that activation of CB
1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy
in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy. |
doi_str_mv | 10.1016/j.neuroscience.2005.01.058 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67831634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306452205001739</els_id><sourcerecordid>17198415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</originalsourceid><addsrcrecordid>eNqNkV9rFDEUxYModlv9CjII-jZjMvkziW-yai0U-lKfQ5K5Y7NkM2uSUfvtm-0O1DcNF0K4v5tzOQehtwR3BBPxYddFWNKcnYfooOsx5h0mHebyGdoQOdB24Iw9RxtMsWgZ7_szdJ7zDtfDGX2JzgiXigreb5DfmhiN9XH2Y25GOCTIuYE_zhdT5nTfPEqVZGLe-5z9HBsL5TdAbModNHmx5c4Es_euiYsLsOTGxPGx9yPMtj4PJgQ_LvkVejGZkOH1el-g71-_3G6_tdc3l1fbT9etY1SVVnGuCBXWguNM0pE4IgSxVOKpZworK4TBhnIqlBx6cJJw1XM7TYoO-FgX6P3p30Oafy6Qi66LOwjBRJiXrMUgKRGU_RMkA1GSEV7BjyfQVdNzgkkfkt-bdK8J1sdE9E7_nYg-JqIx0TWROvxmVVnsHsan0TWCCrxbAZOdCVO12vn8xAnJMOekcp9PHFTzfnlIepUbfQJX9Dj7_9nnAWqwsfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17198415</pqid></control><display><type>article</type><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Freiman, I. ; Szabo, B.</creator><creatorcontrib>Freiman, I. ; Szabo, B.</creatorcontrib><description>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB
1 cannabinoid receptors. The hypothesis of the present work was that CB
1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons.
Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB
1/CB
2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10
−7 M) had no effect on EPSCs. WIN55212-2 (10
−5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10
−5 M) was prevented by the CB
1 antagonist
N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10
−6 M). WIN55212-2 (10
−5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10
−5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10
−3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10
−5 M) did not change the firing of these neurons.
The results show that activation of CB
1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy
in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2005.01.058</identifier><identifier>PMID: 15893652</identifier><identifier>CODEN: NRSCDN</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; basal ganglia ; Benzoxazines ; Biological and medical sciences ; Camphanes - pharmacology ; Cannabinoids - agonists ; Cannabinoids - pharmacology ; catalepsy ; CB 1 cannabinoid receptor ; Dendrites - drug effects ; Electrophysiology ; EPSC ; Excitatory Postsynaptic Potentials - drug effects ; Globus Pallidus - cytology ; Globus Pallidus - drug effects ; Medical sciences ; Mice ; Morpholines - pharmacology ; Naphthalenes - pharmacology ; Neural Pathways - cytology ; Neural Pathways - drug effects ; Neurons - drug effects ; Neurons - physiology ; Neuropharmacology ; patch-clamp ; Patch-Clamp Techniques ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; presynaptic inhibition ; Psychodysleptics: hallucinogen ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrazoles - pharmacology ; Receptor, Cannabinoid, CB1 - drug effects ; Rimonabant ; Subthalamic Nucleus - cytology ; Subthalamic Nucleus - drug effects ; Synaptic Transmission - drug effects</subject><ispartof>Neuroscience, 2005, Vol.133 (1), p.305-313</ispartof><rights>2005 IBRO</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</citedby><cites>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306452205001739$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16840551$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15893652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freiman, I.</creatorcontrib><creatorcontrib>Szabo, B.</creatorcontrib><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB
1 cannabinoid receptors. The hypothesis of the present work was that CB
1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons.
Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB
1/CB
2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10
−7 M) had no effect on EPSCs. WIN55212-2 (10
−5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10
−5 M) was prevented by the CB
1 antagonist
N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10
−6 M). WIN55212-2 (10
−5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10
−5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10
−3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10
−5 M) did not change the firing of these neurons.
The results show that activation of CB
1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy
in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</description><subject>Animals</subject><subject>basal ganglia</subject><subject>Benzoxazines</subject><subject>Biological and medical sciences</subject><subject>Camphanes - pharmacology</subject><subject>Cannabinoids - agonists</subject><subject>Cannabinoids - pharmacology</subject><subject>catalepsy</subject><subject>CB 1 cannabinoid receptor</subject><subject>Dendrites - drug effects</subject><subject>Electrophysiology</subject><subject>EPSC</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>Globus Pallidus - cytology</subject><subject>Globus Pallidus - drug effects</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Morpholines - pharmacology</subject><subject>Naphthalenes - pharmacology</subject><subject>Neural Pathways - cytology</subject><subject>Neural Pathways - drug effects</subject><subject>Neurons - drug effects</subject><subject>Neurons - physiology</subject><subject>Neuropharmacology</subject><subject>patch-clamp</subject><subject>Patch-Clamp Techniques</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>presynaptic inhibition</subject><subject>Psychodysleptics: hallucinogen</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Receptor, Cannabinoid, CB1 - drug effects</subject><subject>Rimonabant</subject><subject>Subthalamic Nucleus - cytology</subject><subject>Subthalamic Nucleus - drug effects</subject><subject>Synaptic Transmission - drug effects</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV9rFDEUxYModlv9CjII-jZjMvkziW-yai0U-lKfQ5K5Y7NkM2uSUfvtm-0O1DcNF0K4v5tzOQehtwR3BBPxYddFWNKcnYfooOsx5h0mHebyGdoQOdB24Iw9RxtMsWgZ7_szdJ7zDtfDGX2JzgiXigreb5DfmhiN9XH2Y25GOCTIuYE_zhdT5nTfPEqVZGLe-5z9HBsL5TdAbModNHmx5c4Es_euiYsLsOTGxPGx9yPMtj4PJgQ_LvkVejGZkOH1el-g71-_3G6_tdc3l1fbT9etY1SVVnGuCBXWguNM0pE4IgSxVOKpZworK4TBhnIqlBx6cJJw1XM7TYoO-FgX6P3p30Oafy6Qi66LOwjBRJiXrMUgKRGU_RMkA1GSEV7BjyfQVdNzgkkfkt-bdK8J1sdE9E7_nYg-JqIx0TWROvxmVVnsHsan0TWCCrxbAZOdCVO12vn8xAnJMOekcp9PHFTzfnlIepUbfQJX9Dj7_9nnAWqwsfw</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Freiman, I.</creator><creator>Szabo, B.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><author>Freiman, I. ; Szabo, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>basal ganglia</topic><topic>Benzoxazines</topic><topic>Biological and medical sciences</topic><topic>Camphanes - pharmacology</topic><topic>Cannabinoids - agonists</topic><topic>Cannabinoids - pharmacology</topic><topic>catalepsy</topic><topic>CB 1 cannabinoid receptor</topic><topic>Dendrites - drug effects</topic><topic>Electrophysiology</topic><topic>EPSC</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>Globus Pallidus - cytology</topic><topic>Globus Pallidus - drug effects</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Morpholines - pharmacology</topic><topic>Naphthalenes - pharmacology</topic><topic>Neural Pathways - cytology</topic><topic>Neural Pathways - drug effects</topic><topic>Neurons - drug effects</topic><topic>Neurons - physiology</topic><topic>Neuropharmacology</topic><topic>patch-clamp</topic><topic>Patch-Clamp Techniques</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>presynaptic inhibition</topic><topic>Psychodysleptics: hallucinogen</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Receptor, Cannabinoid, CB1 - drug effects</topic><topic>Rimonabant</topic><topic>Subthalamic Nucleus - cytology</topic><topic>Subthalamic Nucleus - drug effects</topic><topic>Synaptic Transmission - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freiman, I.</creatorcontrib><creatorcontrib>Szabo, B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freiman, I.</au><au>Szabo, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2005</date><risdate>2005</risdate><volume>133</volume><issue>1</issue><spage>305</spage><epage>313</epage><pages>305-313</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><coden>NRSCDN</coden><abstract>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB
1 cannabinoid receptors. The hypothesis of the present work was that CB
1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons.
Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB
1/CB
2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10
−7 M) had no effect on EPSCs. WIN55212-2 (10
−5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10
−5 M) was prevented by the CB
1 antagonist
N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10
−6 M). WIN55212-2 (10
−5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10
−5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10
−3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10
−5 M) did not change the firing of these neurons.
The results show that activation of CB
1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy
in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15893652</pmid><doi>10.1016/j.neuroscience.2005.01.058</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0306-4522 |
ispartof | Neuroscience, 2005, Vol.133 (1), p.305-313 |
issn | 0306-4522 1873-7544 |
language | eng |
recordid | cdi_proquest_miscellaneous_67831634 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals basal ganglia Benzoxazines Biological and medical sciences Camphanes - pharmacology Cannabinoids - agonists Cannabinoids - pharmacology catalepsy CB 1 cannabinoid receptor Dendrites - drug effects Electrophysiology EPSC Excitatory Postsynaptic Potentials - drug effects Globus Pallidus - cytology Globus Pallidus - drug effects Medical sciences Mice Morpholines - pharmacology Naphthalenes - pharmacology Neural Pathways - cytology Neural Pathways - drug effects Neurons - drug effects Neurons - physiology Neuropharmacology patch-clamp Patch-Clamp Techniques Pharmacology. Drug treatments Piperidines - pharmacology presynaptic inhibition Psychodysleptics: hallucinogen Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyrazoles - pharmacology Receptor, Cannabinoid, CB1 - drug effects Rimonabant Subthalamic Nucleus - cytology Subthalamic Nucleus - drug effects Synaptic Transmission - drug effects |
title | Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A21%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabinoids%20depress%20excitatory%20neurotransmission%20between%20the%20subthalamic%20nucleus%20and%20the%20globus%20pallidus&rft.jtitle=Neuroscience&rft.au=Freiman,%20I.&rft.date=2005&rft.volume=133&rft.issue=1&rft.spage=305&rft.epage=313&rft.pages=305-313&rft.issn=0306-4522&rft.eissn=1873-7544&rft.coden=NRSCDN&rft_id=info:doi/10.1016/j.neuroscience.2005.01.058&rft_dat=%3Cproquest_cross%3E17198415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17198415&rft_id=info:pmid/15893652&rft_els_id=S0306452205001739&rfr_iscdi=true |